Genomic markers for decision making: What is preventing us from using markers?

Nature Reviews Clinical Oncology

Volumn 7, Issue 2, 2010, Pages 90-97

  Coyle, Vicky M ^a   Johnston, Patrick G ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; IRINOTECAN; PANITUMUMAB; PROGESTERONE RECEPTOR;

ADVANCED CANCER; BREAST CANCER; CANCER DIAGNOSIS; CLINICAL DECISION MAKING; CLINICAL PRACTICE; COLORECTAL CANCER; DATA ANALYSIS; DIAGNOSTIC ACCURACY; DRUG TARGETING; EXPERIMENTAL DESIGN; FROZEN SECTION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE TECHNOLOGY; GENETIC HETEROGENEITY; GENETIC MARKER; HUMAN; METASTASIS; MICROARRAY ANALYSIS; NEOPLASM; PREDICTION; PRIMARY TUMOR; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PROGNOSIS; REPRODUCIBILITY; REVIEW; SAMPLE SIZE; SENSITIVITY AND SPECIFICITY; TISSUE PREPARATION; TREATMENT RESPONSE; VALIDATION PROCESS;

BIOLOGICAL MARKERS; DECISION MAKING; GENOMICS; HUMANS;

EID: 76449115854     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2009.214     Document Type: Review

References (65)

1. Pusztai, L. et al. Clinical application of cDNA microarrays in oncology. Oncologist 8, 252-258 (2003).
2. Harris, L. et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J. Clin. Oncol. 25, 5287-5312 (2007). (Pubitemid 350232263)
3. Sotiriou, C. & Pusztai, L. Gene-expression signatures in breast cancer. N. Engl. J. Med. 360, 790-800 (2009).
4. workman, P. & de Bono, J. Targeted therapeutics for cancer treatment: major progress towards personalised molecular medicine. Curr. Opin. Pharmacol. 8, 359-362 (2008).
5. Cunningham, D. et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecanrefractory metastatic colorectal cancer. N. Engl. J. Med. 351, 337-345 (2004).
6. Saltz, L. B. et al. Phase ii trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. 22, 1201-1208 (2004).
7. Chung, K. Y. et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J. Clin. Oncol. 23, 1803-1810 (2005).
8. Khambata-Ford, S. et al. expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J. Clin. Oncol. 25, 3230-3237 (2007).
9. Lievre, A. et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J. Clin. Oncol. 26, 374-379 (2008).
10. Amado, R. G. et al. wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 26, 1626-1634 (2008).
11. Spano, J. P. et al. Potential predictive markers of response to eGFR-targeted therapies in colorectal cancer. Crit. Rev. Oncol. Hematol. 66, 21-30 (2008).
12. Churchill, G. A. Fundamentals of experimental design for cDNA microarrays. Nat. Genet. 32, 490-495 (2002).
13. emmert-Buck, M. R. et al. Laser capture microdissection. Science 274, 998-1001 (1996).
14. Luzzi, V. i., Holtschlag, V. & watson, M. A. Gene expression profiling of primary tumor cell populations using laser capture microdissection, RNA transcript amplification, and GeneChip microarrays. Methods Mol. Biol. 293, 187-207 (2005).
15. Ramaswamy, S. & Golub, T. R. DNA microarrays in clinical oncology. J. Clin. Oncol. 20, 1932-1941 (2002).
16. Mook, S. et al. Daily clinical practice of fresh tumour tissue freezing and gene expression profiling; logistics pilot study preceding the MiNDACT trial. Eur. J. Cancer 45, 1201-1208 (2009).
17. Masuda, N. et al. Analysis of chemical modification of RNA from formalin-fixed samples and optimization of molecular biology applications for such samples. Nucleic Acids Res. 27, 4436-4443 (1999).
18. Oberli, A. et al. expression profiling with RNA from formalin-fixed, paraffin-embedded material. BMC Med. Genomics 1, 9 (2008).
19. Lassmann, S. et al. A novel approach for reliable microarray analysis of microdissected tumor cells from formalin-fixed and paraffin-embedded colorectal cancer resection specimens. J. Mol. Med. 87, 211-224 (2009).
20. Chen, J., Byrne, G. e. Jr & Lossos, i. S. Optimization of RNA extraction from formalinfixed, paraffin-embedded lymphoid tissues. Diagn. Mol. Pathol. 16, 61-72 (2007).
21. Bibikova, M. et al. Quantitative gene expression profiling in formalin-fixed, paraffin-embedded tissues using universal bead arrays. Am. J. Pathol. 165, 1799 - 1807 (2004).
22. Horlings, H. M. et al. Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary. J. Clin. Oncol. 26, 4435-4441 (2008).
23. Farragher, S. M. et al. RNA expression analysis from formalin fixed paraffin embedded tissues. Histochem. Cell. Biol. 130, 435-445 (2008).
24. Scicchitano, M. S. et al. Preliminary comparison of quantity, quality, and microarray performance of RNA extracted from formalin-fixed, paraffinembedded, and unfixed frozen tissue samples. J. Histochem. Cytochem. 54, 1229-1237 (2006).
25. Srivastava, P. K. et al. A cut-off based approach for gene expression analysis of formalin-fixed and paraffin-embedded tissue samples. Genomics 91, 522-529 (2008).
26. Hoshida, Y. et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N. Engl. J. Med. 359, 1995-2004 (2008).
27. Bertucci, F. et al. Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters. Oncogene 23, 1377-1391 (2004).
28. Croner, R. S. et al. Common denominator genes that distinguish colorectal carcinoma from normal mucosa. Int. J. Colorectal Dis. 20, 353-362 (2005).
29. Friederichs, J. et al. Gene expression profiles of different clinical stages of colorectal carcinoma: toward a molecular genetic understanding of tumor progression. Int. J. Colorectal Dis. 20, 391-402 (2005).
30. Groene, J. et al. Transcriptional census of 36 microdissected colorectal cancers yields a gene signature to distinguish UiCC ii and iii. Int. J. Cancer 119, 1829-1836 (2006).
31. Agrawal, D. et al. Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J. Natl Cancer Inst. 94, 513-521 (2002).
32. Ki, D. H. et al. whole genome analysis for liver metastasis gene signatures in colorectal cancer. Int. J. Cancer 121, 2005-2012 (2007).
33. Koh, K. H. et al. Differential gene expression profiles of metastases in paired primary and metastatic colorectal carcinomas. Oncology 75, 92-101 (2008).
34. Koehler, A. et al. Gene expression profiling of colorectal cancer and metastases divides tumours according to their clinicopathological stage. J. Pathol. 204, 65-74 (2004).
35. Matsuyama, R. et al. Predicting 5-fluorouracil chemosensitivity of liver metastases from colorectal cancer using primary tumor specimens: three-gene expression model predicts clinical response. Int. J. Cancer 119, 406-413 (2006).
36. Del Rio, M. et al. Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan. J. Clin. Oncol. 25, 773-780 (2007).
37. Golub, T. R. et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286, 531-537 (1999).
38. Simon, R. et al. Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J. Natl Cancer Inst. 95, 14-18 (2003). (Pubitemid 36124291)
39. Quackenbush, J. Microarray analysis and tumor classification. N. Engl. J. Med. 354, 2463-2472 (2006).
40. eschrich, S. & Yeatman, T. J. DNA microarrays and data analysis: an overview. Surgery 136, 500-503 (2004).
41. Dupuy, A. & Simon, R. M. Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. J. Natl Cancer Inst. 99, 147-157 (2007).
42. Dobbin, K. K., Zhao, Y. & Simon, R. M. How large a training set is needed to develop a classifier for microarray data? Clin. Cancer Res. 14, 108-114 (2008).
43. National institutes of Health. Sample size calculation [online] http://linus.nci.nih.gov/brb/ samplesize/ (2009).
44. wang, Y. et al. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J. Clin. Oncol. 22, 1564-1571 (2004).
45. Hess, K. R. et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J. Clin. Oncol. 24, 4236-4244 (2006).
46. Pusztai, L. & Hess, K. R. Clinical trial design for microarray predictive marker discovery and assessment. Ann. Oncol. 15, 1731-1737 (2004).
47. Taylor, J. M., Ankerst, D. P. & Andridge, R. R. Validation of biomarker-based risk prediction models. Clin. Cancer Res. 14, 5977-5983 (2008).
48. Simon, R. & wang, S. J. Use of genomic signatures in therapeutics development in oncology and other diseases. Pharmacogenomics J. 6, 166-173 (2006).
49. George, S. L. Statistical issues in translational cancer research. Clin. Cancer Res. 14, 5954-5958 (2008).
50. Dobbin, K. K. et al. interlaboratory comparability study of cancer gene expression analysis using oligonucleotide microarrays. Clin. Cancer Res. 11, 565-572 (2005).
51. McShane, L. M. et al. Reporting recommendations for tumor marker prognostic studies (ReMARK). Nat. Clin. Pract. Oncol. 2, 416-422 (2005).
52. Brazma, A. et al. Minimum information about a microarray experiment (MiAMe)-toward standards for microarray data. Nat. Genet. 29, 365-371 (2001).
53. Moher, D., Schulz, K. F. & Altman, D. The CONSORT statement: revised recommendations for improving the quality of reports of parallelgroup randomized trials. JAMA 285, 1987-1991 (2001). (Pubitemid 32366951)
54. Canales, R. D. et al. evaluation of DNA microarray results with quantitative gene expression platforms. Nat. Biotechnol. 24, 1115-1122 (2006).
55. Shi, L. et al. The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat. Biotechnol. 24, 1151-1161 (2006).
56. Shi, L. et al. Reproducible and reliable microarray results through quality control: good laboratory proficiency and appropriate data analysis practices are essential. Curr. Opin. Biotechnol. 19, 10-18 (2008).
57. FDA US Food and Drug Administration. Critical Path Initiative [online] http://www.fda.gov/ ScienceResearch/SpecialTopics/ CriticalPathinitiative/ default.htm (2009).
58. FDA US Food and Drug Administration. Guidance for Industry: Pharmacogenomic Data Submissions [online] http://www.fda.gov/downloads/ Regulatoryinformation/Guidances/ ucm126957.pdf (2009).
59. Geyer, F. C. & Reis-Filho, J. S. Microarray-based gene expression profiling as a clinical tool for breast cancer management: are we there yet? Int. J. Surg. Pathol. 17, 285-302 (2008).
60. Bueno-de-Mesquita, J. M. et al. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTeR). Lancet Oncol. 8, 1079-1087 (2007).
61. Simon, R. The use of genomics in clinical trial design. Clin. Cancer Res. 14, 5984-5993 (2008).
62. Freidlin, B. & Simon, R. Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. Clin. Cancer Res. 11, 7872-7878 (2005).
63. Jiang, w., Freidlin, B. & Simon, R. Biomarkeradaptive threshold design: a procedure for evaluating treatment with possible biomarkerdefined subset effect. J. Natl Cancer Inst. 99, 1036-1043 (2007).
64. Simon, R. Challenges of microarray data and the evaluation of gene expression profile signatures. Cancer Invest. 26, 327-332 (2008).
65. Ransohoff, D. F. How to improve reliability and efficiency of research about molecular markers: roles of phases, guidelines, and study design. J. Clin. Epidemiol. 60, 1205-1219 (2007).